By Fineline Cube 
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (HKG: 1276, SHA: 600276) announced that its independently developed therapeutic biological product, SHR-7782 injection, has received approval from China’s National Medical Products Administration (NMPA) to initiate clinical trials for the treatment of advanced solid tumors.
Drug Profile
SHR-7782 injection is designed to specifically bind to antigens on the surface of tumor cells, enabling targeted tumor cell elimination. This innovative approach positions SHR-7782 as a promising candidate for the treatment of advanced solid tumors.
Market Potential
Currently, there are no similar products approved for marketing either domestically or internationally, highlighting the potential of SHR-7782 to address significant unmet medical needs in oncology.-Fineline Info & Tech